Targeting weaknesses in small cell lung cancer's DNA copying process
Understanding and targeting unique vulnerabilities governing G1/S transition and replication stress in small cell lung cancer
This work looks at whether hitting the DNA-copying stress in small cell lung cancer can make new or existing treatments work better for people with this cancer.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Temple Univ of the Commonwealth NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project ID | NIH-11306664 on NIH RePORTER |
What this research studies
From my perspective, researchers will study why small cell lung cancer cells show high 'replication stress' by focusing on a structural protein called LMNA and on RNA–DNA hybrids called R-loops. They will use lab models of human SCLC (cell lines and related preclinical experiments) to see if low LMNA increases R-loops and DNA damage. The team will then test drugs that change R-loops or target LMNA along with drugs that damage DNA or block repair (like ATR inhibitors) to see if cancer cells become more vulnerable. The goal is to find mechanisms and potential treatment combinations that could eventually guide clinical approaches.
Who could benefit from this research
Good fit: People with small cell lung cancer — especially those whose tumors show signs of replication stress or low LMNA levels — would be the most relevant candidates for follow-up clinical work.
Not a fit: Patients with other lung cancer types or cancers that lack replication stress or the LMNA/R-loop signature are unlikely to benefit from these specific findings.
Why it matters
Potential benefit: If successful, this could point to new drug combinations or biomarkers that make treatments for small cell lung cancer more effective.
How similar studies have performed: Prior preclinical work shows ATR inhibitors and DNA-damaging drugs can exploit replication stress, but directly targeting LMNA or R-loops in SCLC is a newer, less-tested approach.
Where this research is happening
Philadelphia, United States
- Temple Univ of the Commonwealth — Philadelphia, United States (Active)
Researchers
- Principal investigator: Schultz, Christopher William — Temple Univ of the Commonwealth
- Study coordinator: Schultz, Christopher William
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.